Advertisement

Journal of Endocrinological Investigation

, Volume 21, Issue 11, pp 753–757 | Cite as

P53 protein and its messenger ribonucleic acid in human adrenal tumors

  • V. Adleff
  • Károly Rácz
  • M. Tóth
  • I. Varga
  • A. Bezzegh
  • E. Gláz
Article

Abstract

The role of p53 tumor suppressor gene in the pathomechanism of adrenal tumors was investigated by measuring p53 protein and its messenger ribonucleic acid (mRNA) in 12 normal human adrenals as well as in 56 adrenal tumors (7 aldosterone-producing adenomas, 5 adrenocortical adenomas causing Cushing’s syndrome, 19 non-hyperfunctioning adrenocortical adenomas, 5 adrenocortical carcinomas, 12 pheochromocy-tomas, 3 myelolipomas, 4 ganglioneuromas and 1 hemangioma). The p53 protein concentration was significantly increased in aldosterone-producing adenomas (394±36 pg/mg cytosolic protein, mean±SE, vs 266±18 in normal human adrenals), whereas the concentration of this protein in Cushing’s adenomas, non-hyperfunctioning adrenocortical adenomas, pheochromocytomas, and in all but one adrenocortical carcinomas was similar to that measured in normal human adrenal tissues. One adrenocortical carcinoma tissue showed very high p53 protein content (3000 pg/mg cytosolic protein). By contrast, myelolipomas (23±20) ganglioneuromas (43±15) and a hemangioma (11 pg/mg cytosolic protein) had very low p53 protlein content. Northern blot analysis revealed the presence of p53 mRNA in each adrenal tissue examined with highest levels in aldosterone-producing and Cushing’s adenomas. It is possible that the differences in p53 protein and/or mRNA contents reflect corresponding differences in the pathogenetic importance of p53 alterations in these types of adrenal tumors.

Key-words

p53 protein p53 expression luminometric immunoassay adrenal tumors adrenal pathophysiology 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Levine A.J., Momand J., Finlay C.A. The p53 suppressor gene. Nature 351: 453, 1991.PubMedCrossRefGoogle Scholar
  2. 2.
    Lane D.P. p53, guardian of the genome. Nature 358: 15, 1992.PubMedCrossRefGoogle Scholar
  3. 3.
    Bates S., Vousden K.H. p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6: 12, 1996.PubMedCrossRefGoogle Scholar
  4. 4.
    Yano T., Linehan M., Anglard P., Lerman M.I., Daniel L.N., Stein C.A., Robertson C.N., LaRocca R., Zbar B. Genetic changes in human adrenocortical carcinomas. J. Natl. Cancer Inst. 81: 518, 1989.PubMedCrossRefGoogle Scholar
  5. 5.
    Ohgaki H., Kleihues P., Heitz P.U. p53 mutations in sporadic adrenocortical tumors. Int. J. Cancer. 54: 408, 1993.PubMedCrossRefGoogle Scholar
  6. 6.
    Reincke M., Karl M., Travis W.H., Mastorakos G., Allolio B., Linehan H.M., Chrousos G.P. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 78: 790, 1994.PubMedGoogle Scholar
  7. 7.
    Lin S.-R., Lee Y.-J., Tsai J.-H. Mutations of the p53 gene in human functional adrenal neoplasms. J. Clin. Endocrinol. Metab. 78: 483, 1994.PubMedGoogle Scholar
  8. 8.
    Dahia P.L.M., Aguiar R.C.T., Tsanaclis A.M., Bendit I., Bydlowski S.P., Abelin N.M.A., Toledo S.P.A. Molecular and immunohistochemical analysis of p53 in phaeochromocytoma. Br. J. Cancer 72: 1211, 1995.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Glicquel C., Bertagna X., LeBouc Y. Recent advances in the pathogenesis of adrenocortical tumours. Eur. J. Endocrinol. 133: 133, 1995.CrossRefGoogle Scholar
  10. 10.
    Reincke M., Wachenfeld C., Mora P., Thumser A., Jaursch-Hancke C., Abdelhamid S., Chrousos G.P., Allolio B. p53 mutations in adrenal tumors: Caucasian patients do not show the exon 4 “hot spot” found in Taiwan. J. Clin. Endocrinol. Metab. 81: 3636, 1996.PubMedGoogle Scholar
  11. 11.
    Vojtesek B., Fisher C.J., Barnes D.M., Lane D.P. Comparison between p53 staining in tissue sections and p53 levels measured by an ELISA technique. Br. J. Cancer 67: 1254, 1993.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Borg A., Lennerstrand J., Stenmark-Askmalm M., Fernö M., Brisfors A., Öhrvik A., Stai O., Killander D., Lalle D., Brundell J. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br. J. Cancer. 71: 1013, 1995.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294, 1979.PubMedCrossRefGoogle Scholar
  14. 14.
    Chomczynki P., Saachi N. Single step method of RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156, 1997.Google Scholar
  15. 15.
    Rácz K., Pinet F., Marton T., Szende B., Gláz E., Corvol P. Expression of steroidogenic enzyme messenger ribonucleic acids and corticosteroid production in aldosterone-producing and “non-functioning” adrenal adenomas. J. Clin. Endocrinol. Metab. 77: 677, 1993.PubMedGoogle Scholar
  16. 16.
    Baker S.J., Markowitz S., Fealon E.R., Willson J.K., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912, 1990.PubMedCrossRefGoogle Scholar
  17. 17.
    Reincke M., Travis W., Chrousos G.P. Immunohisctochemical evidence for p53 mutations in human adrenal neoplasms. Exp. Clin. Endocrinol. 101(Suppl. 1): 176 (Abs.), 1993.Google Scholar
  18. 18.
    Hildesheim A., Herrero R., Johnson J., Bratti C., Bhatia K., Magrath L.T., Fraumeni J.F. Jr. Elevated levels of p53 protein in adrenocortical carcinomas from Costa Rica. Eur. J. Cancer. 31: 125, 1995.CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1998

Authors and Affiliations

  • V. Adleff
    • 1
  • Károly Rácz
    • 1
  • M. Tóth
    • 1
  • I. Varga
    • 1
  • A. Bezzegh
    • 2
  • E. Gláz
    • 1
    • 2
  1. 1.Gastroenterological and Endocrinological Research Unit, Second Department of MedicineSemmelweis University Medical SchoolBudapestHungary
  2. 2.Byk Gulden Reference LaboratoryNational Institute of OncologyBudapestHungary

Personalised recommendations